Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
In a previous phase II study, patients with pathological stage IIIb (without pleural
effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic
radiotherapy followed by 3 cycles of consolidation therapy with docetaxel. Docetaxel was
selected based upon a survival benefit in patients with recurrent NSCLC.
This trial will evaluate the role of consolidation therapy with docetaxel in patients with
unresectable stage III disease. The purpose of the trial is to evaluate survival and
toxicities of the regimens employed.